{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:37:07Z","timestamp":1783687027923,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T00:00:00Z","timestamp":1182297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T00:00:00Z","timestamp":1182297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11926-007-0041-y","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:30:51Z","timestamp":1182213051000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Uricase and other novel agents for the management of patients with treatment-failure gout"],"prefix":"10.1007","volume":"9","author":[{"given":"John S.","family":"Sundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hershfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,20]]},"reference":[{"key":"41_CR1","first-page":"2303","volume-title":"Arthritis and Allied Conditions: A Textbook of Rheumatology","author":"M.A. Becker","year":"2005","unstructured":"Becker MA, Jolly M: Clinical gout and pathogenesis of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2303\u20132340.","edition":"edn 15"},{"key":"41_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","volume":"12","author":"C.A. Sarawate","year":"2006","unstructured":"Sarawate CA, Patel PA, Schumacher HR, et al.: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61\u201365.","journal-title":"J Clin Rheumatol"},{"key":"41_CR3","first-page":"2041","volume":"33","author":"W. Fang","year":"2006","unstructured":"Fang W, Zeng X, Li M, et al.: The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006, 33:2041\u20132049.","journal-title":"J Rheumatol"},{"key":"41_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00005792-198809000-00004","volume":"67","author":"G.V. Lawry 2nd","year":"1988","unstructured":"Lawry GV 2nd, Fan PT, Bluestone R: Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore) 1988, 67:335\u2013343.","journal-title":"Medicine (Baltimore)"},{"key":"41_CR5","first-page":"562","volume":"33","author":"T.R. Mikuls","year":"2006","unstructured":"Mikuls TR, Curtis JR, Allison JJ, et al.: Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006, 33:562\u2013566.","journal-title":"J Rheumatol"},{"key":"41_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"T.R. Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, et al.: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038\u20131042.","journal-title":"Rheumatology (Oxford)"},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/art.20102","volume":"50","author":"T.R. Mikuls","year":"2004","unstructured":"Mikuls TR, MacLean CH, Olivieri J, et al.: Quality of care indicators for gout management. Arthritis Rheum 2004, 50:937\u2013943.","journal-title":"Arthritis Rheum"},{"key":"41_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11926-996-0046-y","volume":"7","author":"T.R. Mikuls","year":"2005","unstructured":"Mikuls TR, Saag KG: Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?\n                           Curr Rheumatol Rep 2005, 7:242\u2013249.","journal-title":"Curr Rheumatol Rep"},{"key":"41_CR9","first-page":"104","volume":"33","author":"T. Neogi","year":"2006","unstructured":"Neogi T, Hunter DJ, Chaisson CE, et al.: Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006, 33:104\u2013109.","journal-title":"J Rheumatol"},{"key":"41_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s100670050005","volume":"19","author":"B. Pal","year":"2000","unstructured":"Pal B, Foxall M, Dysart T, et al.: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21\u201325.","journal-title":"Clin Rheumatol"},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"C.A. Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925\u2013934.","journal-title":"Mayo Clin Proc"},{"key":"41_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1440-1762.2000.00353.x","volume":"20","author":"P. Smith","year":"2000","unstructured":"Smith P, Karlson N, Nair BR: Quality use of allopurinol in the elderly. J Qual Clin Pract 2000, 20:42\u201343.","journal-title":"J Qual Clin Pract"},{"key":"41_CR13","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M.A. Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450\u20132461.","journal-title":"N Engl J Med"},{"key":"41_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"K.R. Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47\u201356.","journal-title":"Am J Med"},{"key":"41_CR15","first-page":"1646","volume":"33","author":"N. Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646\u20131650.","journal-title":"J Rheumatol"},{"key":"41_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J. Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981\u2013983.","journal-title":"Ann Rheum Dis"},{"key":"41_CR17","first-page":"2341","volume-title":"Arthritis and Allied Conditions: A Textbook of Rheumatology","author":"P.C. Hahn","year":"2005","unstructured":"Hahn PC, Edwards NL: Management of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2341\u20132355.","edition":"edn 15"},{"key":"41_CR18","first-page":"44","volume":"30","author":"E. de Klerk","year":"2003","unstructured":"de Klerk E, van der Heijde D, Landewe R, et al.: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003, 30:44\u201354.","journal-title":"J Rheumatol"},{"key":"41_CR19","first-page":"1575","volume":"31","author":"A.A. Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Joseph-Ridge N, et al.: Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004, 31:1575\u20131581.","journal-title":"J Rheumatol"},{"key":"41_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.2005.038653","volume":"65","author":"J.S. Sundy","year":"2006","unstructured":"Sundy JS, Becker MA, Schumacher HR, et al.: Multicenter longitudinal study of disease characteristics in patients with treatment failure gout. Ann Rheum Dis 2006, 65:272.","journal-title":"Ann Rheum Dis"},{"key":"41_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1136\/ard.2005.038158","volume":"65","author":"J.S. Sundy","year":"2006","unstructured":"Sundy JS, Schumacher HR, Becker MA, et al.: Quality of life in patients with treatment failure gout. Ann Rheum Dis 2006, 65:271.","journal-title":"Ann Rheum Dis"},{"key":"41_CR22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1081\/NCN-200027372","volume":"23","author":"M.A. Becker","year":"2004","unstructured":"Becker MA, Kisicki J, Khosravan R, et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23:1111\u20131116.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"41_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"M.A. Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916\u2013923.","journal-title":"Arthritis Rheum"},{"key":"41_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S. Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, et al.: PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23:1117\u20131118.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"41_CR25","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","volume":"78","author":"B.N. Ames","year":"1981","unstructured":"Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858\u20136862.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1073\/pnas.91.2.742","volume":"91","author":"X. Wu","year":"1994","unstructured":"Wu X, Wakamiya M, Vaishnav S, et al.: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994, 91:742\u2013746.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","volume":"12","author":"S.J. Kelly","year":"2001","unstructured":"Kelly SJ, Delnomdedieu M, Oliverio MI, et al.: Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001\u20131009.","journal-title":"J Am Soc Nephrol"},{"key":"41_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","volume":"25","author":"J.D. Moolenburgh","year":"2006","unstructured":"Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749\u2013752.","journal-title":"Clin Rheumatol"},{"key":"41_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ncprheum0214","volume":"2","author":"P. Richette","year":"2006","unstructured":"Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006, 2:338\u2013342; quiz 343.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"41_CR30","first-page":"392","volume":"62","author":"S. Rozenberg","year":"1995","unstructured":"Rozenberg S, Roche B, Dorent R, et al.: Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995, 62:392\u2013394.","journal-title":"Rev Rhum Engl Ed"},{"key":"41_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/ndt\/gfh629","volume":"20","author":"B. Vogt","year":"2005","unstructured":"Vogt B: Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005, 20:431\u2013433.","journal-title":"Nephrol Dial Transplant"},{"key":"41_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(81)90528-6","volume":"2","author":"S. Davis","year":"1981","unstructured":"Davis S, Park YK, Abuchowski A, Davis FF: Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981, 2:281\u2013283.","journal-title":"Lancet"},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-109-2-114","volume":"109","author":"C.C. Chua","year":"1988","unstructured":"Chua CC, Greenberg ML, Viau AT, et al.: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 109:114\u2013117.","journal-title":"Ann Intern Med"},{"key":"41_CR34","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1861","volume":"8","author":"N.J. Ganson","year":"2006","unstructured":"Ganson NJ, Kelly SJ, Scarlett E, et al.: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12.","journal-title":"Arthritis Res Ther"},{"key":"41_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"J.S. Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021\u20131028.","journal-title":"Arthritis Rheum"},{"key":"41_CR36","doi-asserted-by":"publisher","first-page":"S679","DOI":"10.1002\/art.20959","volume":"52","author":"J.S. Sundy","year":"2005","unstructured":"Sundy JS, Becker MA, Baraf HS, et al.: A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout [abstract]. Arthritis Rheum 2005, 52:S679.","journal-title":"Arthritis Rheum"},{"key":"41_CR37","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1002\/art.20724","volume":"52","author":"H.S. Baraf","year":"2005","unstructured":"Baraf HS, Kim S, Matsumoto AK, Maroli AN: Resolution of tophi with intravenous PEG-uricase in refractory gout [abstract]. Arthritis Rheum 2005, 52:S105.","journal-title":"Arthritis Rheum"},{"key":"41_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F. Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, et al.: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356\u2013360.","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0041-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-007-0041-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0041-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0041-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T12:48:33Z","timestamp":1652618913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-007-0041-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,20]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11926-007-0041-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,20]]},"assertion":[{"value":"20 June 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}